Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High price for Fuzeon

Executive Summary

Roche is making HIV agent Fuzeon (T-20) available in Europe under a pre-license sales program for a price of approximately $50 per day. If that price is a benchmark for the U.S. launch price, it would significantly exceed the cost of other HIV therapies. Roche says the premium price is necessary because "Fuzeon is one of the most complex and challenging molecules ever chemically manufactured by the pharmaceutical industry at large scale, requiring 45 kg of raw materials for 1 kg of Fuzeon, and more than 100 production steps"...

You may also be interested in...



Roche Fuzeon Approval Presents Challenges Of Reimbursement, Supply

AIDS Drug Assistance Program coverage of Roche's antiretroviral Fuzeon could hinge upon the agent's role as either replacement or add-on therapy

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel